Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, Sanjay, Baruah, Manash P., Sahay, Rakesh K., Unnikrishnan, Ambika Gopalakrishnan, Uppal, Shweta, Adetunji, Omolara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792029/
https://www.ncbi.nlm.nih.gov/pubmed/27042424
http://dx.doi.org/10.4103/2230-8210.176351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792029/
https://www.ncbi.nlm.nih.gov/pubmed/27042424
http://dx.doi.org/10.4103/2230-8210.176351

Ejemplares similares